Defining the molecular basis of tumor metabolism: a continuing challenge since Warburg's discovery

Ana Carolina Santos de Souza1, Giselle Zenker Justo, Daniele Ribeiro de Araújo

  • 1Centro de Ciências Naturais e Humanas (CCNH), Universidade Federal do ABC (UFABC), Santo André, SP Brasil. ana.galvao@ufabc.edu.br

Insights

Cancer cells reprogram their metabolism due to genetic changes, impacting cell functions. Understanding tumor metabolism offers new therapeutic strategies for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer arises from genetic mutations disrupting cell signaling pathways.
  • Traditional therapies face challenges like side effects and drug resistance due to shared pathways in normal and cancer cells.
  • Altered tumor metabolism is a recognized hallmark of cancer, linked to oncogenes and tumor suppressors.

Purpose of the Study:

  • To review tumor metabolism from a molecular viewpoint, focusing on oncogenes, tumor suppressors, and signaling pathways.
  • To identify key unanswered questions in cancer metabolism research.
  • To explore the potential of targeting tumor metabolism for novel cancer treatments.

Main Methods:

  • Literature review focusing on molecular mechanisms of cancer metabolism.
  • Analysis of signaling pathways involved in metabolic transformation and tumorigenesis.
  • Discussion of current understanding and future research directions.

Main Results:

  • Cancer cells exhibit significant metabolic reprogramming, a direct consequence of oncogenic and tumor suppressor activity.
  • Metabolic transformation is intrinsically linked to tumorigenesis and cancer progression.
  • Despite progress, a complete understanding of cancer metabolism remains elusive.

Conclusions:

  • Tumor metabolism is a complex and incompletely understood area crucial to cancer development.
  • Targeting cancer-specific metabolic alterations presents a promising strategy for developing novel and effective cancer therapies.
  • Further research into the molecular underpinnings of tumor metabolism is essential for advancing cancer treatment.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...